Ignite Creation Date:
2024-07-17 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06484777
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-06-26
Brief Title:
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Sponsor:
Suzhou Suncadia Biopharmaceuticals Co Ltd
Organization:
Suzhou Suncadia Biopharmaceuticals Co Ltd
Study Overview
Official Title:
An Open-label Multi-center Phase I Clinical Study of the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of SHR-9539 Injection in Patients With Multiple Myeloma
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a multicenter open-label dose-escalationdose-expansion clinical Phase I trial designed to evaluate the safety tolerability pharmacokinetics pharmacodynamics and efficacy profile of SHR-9539 Injection in patients with multiple myeloma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None